
    
      Patients who have completed a limited duration study (less than 12 months of continuous
      treatment) of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or
      symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their
      regimen of vesnarinone for 12 months beyond their original participation.
    
  